AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

Entasis Therapeutics to Present at the 39th Annual Cowen Healthcare Conference

March 6, 2019

WALTHAM, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer, will present at the 39th Annual Cowen Healthcare Conference being held March 11-13, 2019 in Boston, Massachusetts.

Details of the presentations are below:Event: 39th Annual Cowen Healthcare ConferenceDate: March 11, 2019Time: 2:50 – 3:20 PM ET

A live webcast of the presentation can be accessed under “Investors & Media” in the “News & Events” section of the Company’s website at www.entasistx.com. An archived replay of the webcast will be available on its website for 30 days after the conference.

In addition to his presentation, Dr. Perros will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Company management should contact their Cowen representatives.

About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit www.entasistx.com.

Entasis Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com

Investor Relations ContactLee RothThe Ruth Group646-536-7012 lroth@theruthgroup.com

Media ContactKirsten ThomasThe Ruth Group(508) 280-6592 kthomas@theruthgroup.com